We evaluated the distribution of the apoAII-isoforms, CA19–9, and DUAPN-2 in patients who would be considered at risk for pancreatic malignancy, such as those with pancreatic endocrine neoplasms, intraductal papillary mucinous neoplasms (IPMNs), mucinous cystic neoplasms (MCNs), serous cystic neoplasms (SCNs), chronic pancreatitis, and other conditions. Here, APOA2 is linked to pancreatic neuroendocrine neoplasm.